Repligen Corporation (RGEN) 10-Year Financial Performance & Capital Metrics

RGEN • • Industrial / General

HealthcareMedical InstrumentsBiopharma & Life Science ToolsBioprocessing & Cell Therapy Tools

AboutRepligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.Show more

Revenue $634M +0.3%
EBITDA $51M -61.6%
Net Income -$26M -171.7%
EPS (Diluted) -0.46 -173.0%
Gross Margin 43.29% -1.7%
EBITDA Margin 8.11% -61.7%
Operating Margin -5.53% -173.4%
Net Margin -4.02% -171.4%
ROE -1.3% -170.5%
ROIC -1.38% -171.9%
Debt/Equity 0.35 -4.0%
Interest Coverage -1.56 -132.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 22.5% free cash flow margin
✓Strong 5Y sales CAGR of 18.6%
✓Healthy 5Y average net margin of 12.1%

✗Weaknesses

✗Weak 3Y average ROE of 3.6%
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y25.87%

5Y18.61%

3Y-1.83%

TTM13.69%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM110.14%

EPS CAGR

10Y-

5Y-

3Y-

TTM148.54%

ROCE

10Y Avg15.14%

5Y Avg5.31%

3Y Avg3.87%

Latest-1.31%

Peer Comparison

Bioprocessing & Cell Therapy Tools

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
BLFSBioLife Solutions, Inc.	1.18B	24.47	-55.61	-42.59%	-4.33%	-0.91%	0.44%	0.09
RGENRepligen Corporation	9.1B	161.69	-351.50	0.33%	0.25%	0.08%	1.57%	0.35

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	83.54M	104.54M	141.24M	194.03M	270.25M	366.26M	670.53M	801.54M	632.36M	634.44M
Revenue Growth %	0.31%	0.25%	0.35%	0.37%	0.39%	0.36%	0.83%	0.2%	-0.21%	0%
Cost of Goods Sold+	35.25M	47.12M	67.05M	85.95M	132.02M	171.91M	279.28M	345.83M	353.92M	359.79M
COGS % of Revenue	0.42%	0.45%	0.47%	0.44%	0.49%	0.47%	0.42%	0.43%	0.56%	0.57%
Gross Profit+	48.29M	57.42M	74.19M	108.08M	138.22M	194.35M	391.25M	455.71M	278.44M	274.64M
Gross Margin %	0.58%	0.55%	0.53%	0.56%	0.51%	0.53%	0.58%	0.57%	0.44%	0.43%
Gross Profit Growth %	0.36%	0.19%	0.29%	0.46%	0.28%	0.41%	1.01%	0.16%	-0.39%	-0.01%
Operating Expenses+	30.44M	38.21M	60.18M	82.09M	98.14M	113.07M	224M	231.04M	230.74M	309.76M
OpEx % of Revenue	0.36%	0.37%	0.43%	0.42%	0.36%	0.31%	0.33%	0.29%	0.36%	0.49%
Selling, General & Admin	24.7M	30.85M	51.51M	66.32M	78.69M	93.41M	183.87M	215.83M	218.58M	263.37M
SG&A % of Revenue	0.3%	0.3%	0.36%	0.34%	0.29%	0.26%	0.27%	0.27%	0.35%	0.42%
Research & Development	5.74M	7.36M	8.67M	15.77M	19.45M	19.66M	34.27M	43.94M	42.72M	43.2M
R&D % of Revenue	0.07%	0.07%	0.06%	0.08%	0.07%	0.05%	0.05%	0.05%	0.07%	0.07%
Other Operating Expenses	0	0	0	262K	0	0	5.87M	-28.73M	-30.57M	3.19M
Operating Income+	13.76M	15.97M	14.01M	25.99M	40.08M	81.29M	167.25M	224.67M	47.7M	-35.11M
Operating Margin %	0.16%	0.15%	0.1%	0.13%	0.15%	0.22%	0.25%	0.28%	0.08%	-0.06%
Operating Income Growth %	0.29%	0.16%	-0.12%	0.86%	0.54%	1.03%	1.06%	0.34%	-0.79%	-1.74%
EBITDA+	18.36M	21.31M	24.46M	41.77M	60.95M	108.36M	205.7M	281.68M	133.82M	51.45M
EBITDA Margin %	0.22%	0.2%	0.17%	0.22%	0.23%	0.3%	0.31%	0.35%	0.21%	0.08%
EBITDA Growth %	0.25%	0.16%	0.15%	0.71%	0.46%	0.78%	0.9%	0.37%	-0.52%	-0.62%
D&A (Non-Cash Add-back)	4.59M	5.33M	10.45M	15.78M	20.87M	27.07M	38.45M	57.01M	86.11M	86.56M
EBIT	13.46M	19.22M	13.69M	25.99M	35.44M	71.35M	164.82M	220.3M	59.21M	-6.3M
Net Interest Income+	-32K	-3.77M	-6.44M	-6.71M	-9.29M	-10.39M	-12.54M	4M	-10.03M	-22.57M
Interest Income	0	0	0	0	0	1.74M	176K	6.98M	0	0
Interest Expense	32K	3.77M	6.44M	6.71M	9.29M	12.13M	12.71M	2.98M	10.03M	22.57M
Other Income/Expense	-341K	-4.28M	-6.76M	-4.55M	-13.93M	-22.07M	-13.71M	-5.53M	9M	8.08M
Pretax Income+	13.42M	11.69M	7.25M	21.44M	26.15M	59.22M	153.54M	219.14M	56.71M	-27.04M
Pretax Margin %	0.16%	0.11%	0.05%	0.11%	0.1%	0.16%	0.23%	0.27%	0.09%	-0.04%
Income Tax+	4.08M	11K	-21.11M	4.82M	4.74M	-709K	25.25M	33.18M	21.11M	-1.52M
Effective Tax Rate %	0.7%	1%	3.91%	0.78%	0.82%	1.01%	0.84%	0.85%	0.63%	0.94%
Net Income+	9.35M	11.68M	28.35M	16.62M	21.41M	59.93M	128.29M	185.96M	35.6M	-25.51M
Net Margin %	0.11%	0.11%	0.2%	0.09%	0.08%	0.16%	0.19%	0.23%	0.06%	-0.04%
Net Income Growth %	0.14%	0.25%	1.43%	-0.41%	0.29%	1.8%	1.14%	0.45%	-0.81%	-1.72%
Net Income (Continuing)	9.35M	11.68M	28.35M	16.62M	21.41M	59.93M	128.29M	185.96M	35.6M	-25.51M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.28	0.34	0.72	0.37	0.44	1.11	2.24	3.24	0.63	-0.46
EPS Growth %	0.12%	0.21%	1.12%	-0.49%	0.19%	1.52%	1.02%	0.45%	-0.81%	-1.73%
EPS (Basic)	0.28	0.35	0.74	0.38	0.44	1.14	2.33	3.35	0.64	-0.46
Diluted Shares Outstanding	33.58M	34.1M	39.15M	45.47M	49.21M	53.89M	57.26M	57.45M	56.38M	55.94M
Basic Shares Outstanding	32.88M	33.57M	38.23M	43.77M	48.34M	52.55M	55.02M	55.46M	55.72M	55.94M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	103.25M	184.15M	242.78M	275.74M	641.83M	902.38M	931.68M	998.12M	1.11B	1.07B
Cash & Short-Term Investments	73.41M	141.78M	173.76M	193.82M	528.39M	717.29M	603.81M	623.76M	751.32M	757.36M
Cash Only	73.41M	141.78M	173.76M	193.82M	528.39M	717.29M	603.81M	523.46M	751.32M	757.36M
Short-Term Investments	0	0	0	0	0	0	0	100.3M	0	0
Accounts Receivable	11.45M	16.03M	27.74M	35.75M	43.67M	71.39M	117.42M	116.25M	124.16M	134.12M
Days Sales Outstanding	50.01	55.98	71.68	67.26	58.98	71.14	63.92	52.94	71.67	77.16
Inventory	18M	24.7M	39M	42.26M	54.83M	95.03M	184.49M	238.28M	202.32M	142.96M
Days Inventory Outstanding	186.36	191.31	212.33	179.47	151.6	201.76	241.12	251.49	208.65	145.03
Other Current Assets	917K	662K	1.38M	2.43M	12.13M	14.09M	19.27M	17.41M	19.92M	20.6M
Total Non-Current Assets+	42.98M	104.76M	500.74M	498.88M	758.28M	1B	1.43B	1.53B	1.72B	1.76B
Property, Plant & Equipment	13.8M	14.96M	22.42M	32.18M	74.16M	92.05M	226.52M	315.7M	322.95M	333.12M
Fixed Asset Turnover	6.05x	6.99x	6.30x	6.03x	3.64x	3.98x	2.96x	2.54x	1.96x	1.90x
Goodwill	14.35M	59.55M	327.33M	326.74M	468.41M	618.3M	860.36M	855.51M	987.12M	1.03B
Intangible Assets	12.76M	29.81M	144.75M	135.44M	212.55M	287.1M	337.27M	360.62M	406.96M	397.9M
Long-Term Investments	1.63M	450K	0	0	0	0	0	0	0	0
Other Non-Current Assets	450K	450K	6.23M	174K	238K	573K	615K	815K	1.28M	868K
Total Assets+	146.24M	288.91M	120.41M	139.45M	1.4B	1.9B	2.36B	2.53B	2.83B	2.83B
Asset Turnover	0.57x	0.36x	1.17x	1.39x	0.19x	0.19x	0.28x	0.32x	0.22x	0.22x
Asset Growth %	3.24%	0.98%	-0.58%	0.16%	9.04%	0.36%	0.24%	0.07%	0.12%	-0%
Total Current Liabilities+	18.78M	21.07M	25.21M	129.84M	48.31M	318.96M	375.26M	404.2M	164.94M	126.79M
Accounts Payable	6.72M	5.06M	7.28M	10.49M	11.43M	16.88M	36.2M	27.55M	19.56M	32.13M
Days Payables Outstanding	69.62	39.21	39.64	44.54	31.59	35.84	47.31	29.08	20.18	32.6
Short-Term Debt	0	0	0	103.49M	0	243.74M	255.26M	284.62M	69.45M	0
Deferred Revenue (Current)	258K	408K	960K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	4.68M	5.59M	9.56M	9.95M	19.85M	20.29M	42.15M	47.47M	29.64M	49.29M
Current Ratio	5.50x	8.74x	9.63x	2.12x	13.28x	2.83x	2.48x	2.47x	6.74x	8.41x
Quick Ratio	4.54x	7.57x	8.08x	1.80x	12.15x	2.53x	1.99x	1.88x	5.51x	7.28x
Cash Conversion Cycle	166.74	208.08	244.37	202.18	178.99	237.07	257.72	275.34	260.14	189.59
Total Non-Current Liabilities+	4.71M	99.07M	126.76M	29.21M	292.03M	54.78M	233.03M	216.7M	701.4M	730.16M
Long-Term Debt	0	95.27M	99.25M	0	232.77M	0	0	0	510.14M	525.57M
Capital Lease Obligations	0	0	0	0	27M	26.43M	102.49M	131.39M	126.58M	145.58M
Deferred Tax Liabilities	0	0	25.17M	25.09M	29.94M	27.03M	33.48M	23M	39.32M	22.77M
Other Non-Current Liabilities	4.71M	3.8M	2.34M	4.13M	2.33M	1.32M	97.05M	62.31M	25.35M	36.24M
Total Liabilities	23.49M	120.15M	151.97M	159.05M	340.35M	373.74M	608.29M	620.9M	866.34M	856.95M
Total Debt+	0	95.27M	99.25M	103.49M	263.32M	275.42M	366.05M	422.96M	711.8M	686.25M
Net Debt	-73.41M	-46.51M	-74.51M	-90.33M	-265.07M	-441.88M	-237.76M	-100.5M	-39.52M	-71.11M
Debt / Equity	-	0.56x	0.17x	0.17x	0.25x	0.18x	0.21x	0.22x	0.36x	0.35x
Debt / EBITDA	-	4.47x	4.06x	2.48x	4.32x	2.54x	1.78x	1.50x	5.32x	13.34x
Net Debt / EBITDA	-4.00x	-2.18x	-3.05x	-2.16x	-4.35x	-4.08x	-1.16x	-0.36x	-0.30x	-1.38x
Interest Coverage	430.13x	4.24x	2.17x	3.87x	4.31x	6.70x	13.15x	75.47x	4.76x	-1.56x
Total Equity+	122.75M	168.76M	591.55M	615.57M	1.06B	1.53B	1.75B	1.91B	1.96B	1.97B
Equity Growth %	0.1%	0.37%	2.51%	0.04%	0.72%	0.44%	0.14%	0.09%	0.03%	0%
Book Value per Share	3.66	4.95	15.11	13.54	21.54	28.37	30.56	33.26	34.85	35.27
Total Shareholders' Equity	122.75M	168.76M	591.55M	615.57M	1.06B	1.53B	1.75B	1.91B	1.96B	1.97B
Common Stock	329K	338K	436K	439K	521K	548K	553K	556K	558K	561K
Retained Earnings	-71.54M	-59.86M	-31.51M	-15.57M	5.84M	65.77M	194.06M	397.27M	432.87M	407.35M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-8.57M	-13.75M	-6.36M	-11.89M	-15.03M	2.08M	-16.89M	-34.39M	-37.81M	-52.53M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	15.05M	7.52M	17.45M	32.77M	67.22M	62.63M	119.02M	172.08M	113.92M	175.39M
Operating CF Margin %	0.18%	0.07%	0.12%	0.17%	0.25%	0.17%	0.18%	0.21%	0.18%	0.28%
Operating CF Growth %	-0.18%	-0.5%	1.32%	0.88%	1.05%	-0.07%	0.9%	0.45%	-0.34%	0.54%
Net Income	9.35M	11.68M	28.35M	16.62M	21.41M	59.93M	128.29M	185.96M	41.58M	-25.51M
Depreciation & Amortization	4.59M	5.33M	10.51M	15.78M	20.87M	27.07M	38.45M	57.01M	68.08M	86.56M
Stock-Based Compensation	3.6M	4.59M	6.75M	10.19M	12.85M	17.01M	0	27.32M	25.57M	48.07M
Deferred Taxes	-118K	-4.09M	-24.68M	71K	-624K	-3.99M	6.52M	-1.35M	2.32M	0
Other Non-Cash Items	4.08M	5.51M	4.04M	4.25M	15.33M	11.97M	47.89M	-27.01M	-15M	5.36M
Working Capital Changes	-6.45M	-15.51M	-7.52M	-14.13M	-2.62M	-49.35M	-102.13M	-69.84M	-8.64M	60.92M
Change in Receivables	-3.73M	-3.22M	-6.89M	-6.1M	-5.68M	-20.89M	-46.52M	-3.6M	-3.31M	-14.03M
Change in Inventory	-6.15M	-6.16M	605K	-4.04M	-10.8M	-29.99M	-89.78M	-57.2M	40.97M	56.9M
Change in Payables	3.02M	-1.8M	807K	2.27M	662K	2.46M	19.52M	-8.2M	-9.8M	12.9M
Cash from Investing+	4.79M	-49.19M	-98.25M	-14.04M	-205.31M	-201.38M	-221.17M	-233.24M	-123.28M	-86.38M
Capital Expenditures	-2.63M	-4.33M	-5.45M	-14.04M	-18.5M	-22.45M	-71.28M	-84.83M	-36.22M	-25.68M
CapEx % of Revenue	0.03%	0.04%	0.04%	0.07%	0.07%	0.06%	0.11%	0.11%	0.06%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	27.59M	45K	450K	-3.4M	-4.65M	-3.89M	0	-48.4M	-2.73M	-5.94M
Cash from Financing+	767K	112.11M	129.94M	3.41M	484.87M	305.92M	961K	-13.34M	248.96M	-82.9M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	767K	1.04M	636K	3.42M	677K	8.14M	-2.9M	-13.34M	-26.75M	-17.26M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	12.43M	3.2M	12M	18.73M	44.06M	36.28M	47.74M	38.74M	74.93M	142.49M
FCF Margin %	0.15%	0.03%	0.08%	0.1%	0.16%	0.1%	0.07%	0.05%	0.12%	0.22%
FCF Growth %	-0.03%	-0.74%	2.75%	0.56%	1.35%	-0.18%	0.32%	-0.19%	0.93%	0.9%
FCF per Share	0.37	0.09	0.31	0.41	0.90	0.67	0.83	0.67	1.33	2.55
FCF Conversion (FCF/Net Income)	1.61x	0.64x	0.62x	1.97x	3.14x	1.05x	0.93x	0.93x	3.20x	-6.87x
Interest Paid	0	1.22M	2.44M	2.44M	1.48M	1.07M	0	1.03M	988K	6.07M
Taxes Paid	4.95M	3.99M	4.02M	4.05M	6.5M	10.28M	0	34.37M	26.96M	19.3M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	7.97%	8.01%	7.46%	2.75%	2.56%	4.63%	7.82%	10.16%	1.84%	-1.3%
Return on Invested Capital (ROIC)	20.84%	13.96%	3.29%	3.74%	4.56%	6.48%	9.65%	10.14%	1.92%	-1.38%
Gross Margin	57.8%	54.93%	52.53%	55.7%	51.15%	53.06%	58.35%	56.85%	44.03%	43.29%
Net Margin	11.19%	11.17%	20.07%	8.56%	7.92%	16.36%	19.13%	23.2%	5.63%	-4.02%
Debt / Equity	-	0.56x	0.17x	0.17x	0.25x	0.18x	0.21x	0.22x	0.36x	0.35x
Interest Coverage	430.13x	4.24x	2.17x	3.87x	4.31x	6.70x	13.15x	75.47x	4.76x	-1.56x
FCF Conversion	1.61x	0.64x	0.62x	1.97x	3.14x	1.05x	0.93x	0.93x	3.20x	-6.87x
Revenue Growth	31.45%	25.14%	35.1%	37.38%	39.28%	35.53%	83.08%	19.54%	-21.11%	0.33%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	270.1M	366.14M	670.32M	801.18M	638.38M	634.18M
Product Growth	-	-	-	-	35.56%	83.08%	19.52%	-20.32%	-0.66%
Filtration Products	19.77M	49.05M	90.59M	119.53M	174.9M	403.5M	495.93M	347.78M	372.96M
Filtration Products Growth	-	148.05%	84.68%	31.96%	46.31%	130.71%	22.91%	-29.87%	7.24%
Chromatography Products	29.52M	36.31M	45.33M	64.64M	73.55M	91.04M	131.68M	126.63M	122.81M
Chromatography Products Growth	-	23.00%	24.83%	42.60%	13.79%	23.77%	44.64%	-3.84%	-3.02%
Proteins Products	-	-	-	65.12M	80.73M	123.71M	114.32M	103.46M	74.42M
Proteins Products Growth	-	-	-	-	23.97%	53.23%	-7.59%	-9.50%	-28.07%
Process Analytics Products	-	-	-	16.41M	33.35M	48.02M	53.51M	56.82M	59.3M
Process Analytics Products Growth	-	-	-	-	103.27%	44.00%	11.44%	6.18%	4.37%
Other products	431K	1.76M	3.6M	4.4M	3.61M	4.05M	5.74M	3.69M	4.68M
Other products Growth	-	308.58%	104.66%	22.06%	-17.91%	12.18%	41.72%	-35.76%	26.87%
Protein Products	54.72M	53.97M	54.38M	-	-	-	-	-	-
Protein Products Growth	-	-1.37%	0.75%	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Repligen Corporation (RGEN) reported $707.9M in revenue for fiscal year 2024. This represents a 2494% increase from $27.3M in 2011.

Repligen Corporation (RGEN) grew revenue by 0.3% over the past year. Growth has been modest.

Yes, Repligen Corporation (RGEN) is profitable, generating $1.7M in net income for fiscal year 2024 (-4.0% net margin).

Dividend & Returns

Repligen Corporation (RGEN) has a return on equity (ROE) of -1.3%. Negative ROE indicates the company is unprofitable.

Repligen Corporation (RGEN) generated $106.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Repligen Corporation (RGEN) 10-Year Financial Performance & Capital Metrics

RGEN • • Industrial / General

HealthcareMedical InstrumentsBiopharma & Life Science ToolsBioprocessing & Cell Therapy Tools

Revenue $634M +0.3%
EBITDA $51M -61.6%
Net Income -$26M -171.7%
EPS (Diluted) -0.46 -173.0%
Gross Margin 43.29% -1.7%
EBITDA Margin 8.11% -61.7%
Operating Margin -5.53% -173.4%
Net Margin -4.02% -171.4%
ROE -1.3% -170.5%
ROIC -1.38% -171.9%
Debt/Equity 0.35 -4.0%
Interest Coverage -1.56 -132.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 22.5% free cash flow margin
✓Strong 5Y sales CAGR of 18.6%
✓Healthy 5Y average net margin of 12.1%

✗Weaknesses

✗Weak 3Y average ROE of 3.6%
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y25.87%

5Y18.61%

3Y-1.83%

TTM13.69%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM110.14%

EPS CAGR

10Y-

5Y-

3Y-

TTM148.54%

ROCE

10Y Avg15.14%

5Y Avg5.31%

3Y Avg3.87%

Latest-1.31%

Peer Comparison

Bioprocessing & Cell Therapy Tools

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
BLFSBioLife Solutions, Inc.	1.18B	24.47	-55.61	-42.59%	-4.33%	-0.91%	0.44%	0.09
RGENRepligen Corporation	9.1B	161.69	-351.50	0.33%	0.25%	0.08%	1.57%	0.35

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	83.54M	104.54M	141.24M	194.03M	270.25M	366.26M	670.53M	801.54M	632.36M	634.44M
Revenue Growth %	0.31%	0.25%	0.35%	0.37%	0.39%	0.36%	0.83%	0.2%	-0.21%	0%
Cost of Goods Sold+	35.25M	47.12M	67.05M	85.95M	132.02M	171.91M	279.28M	345.83M	353.92M	359.79M
COGS % of Revenue	0.42%	0.45%	0.47%	0.44%	0.49%	0.47%	0.42%	0.43%	0.56%	0.57%
Gross Profit+	48.29M	57.42M	74.19M	108.08M	138.22M	194.35M	391.25M	455.71M	278.44M	274.64M
Gross Margin %	0.58%	0.55%	0.53%	0.56%	0.51%	0.53%	0.58%	0.57%	0.44%	0.43%
Gross Profit Growth %	0.36%	0.19%	0.29%	0.46%	0.28%	0.41%	1.01%	0.16%	-0.39%	-0.01%
Operating Expenses+	30.44M	38.21M	60.18M	82.09M	98.14M	113.07M	224M	231.04M	230.74M	309.76M
OpEx % of Revenue	0.36%	0.37%	0.43%	0.42%	0.36%	0.31%	0.33%	0.29%	0.36%	0.49%
Selling, General & Admin	24.7M	30.85M	51.51M	66.32M	78.69M	93.41M	183.87M	215.83M	218.58M	263.37M
SG&A % of Revenue	0.3%	0.3%	0.36%	0.34%	0.29%	0.26%	0.27%	0.27%	0.35%	0.42%
Research & Development	5.74M	7.36M	8.67M	15.77M	19.45M	19.66M	34.27M	43.94M	42.72M	43.2M
R&D % of Revenue	0.07%	0.07%	0.06%	0.08%	0.07%	0.05%	0.05%	0.05%	0.07%	0.07%
Other Operating Expenses	0	0	0	262K	0	0	5.87M	-28.73M	-30.57M	3.19M
Operating Income+	13.76M	15.97M	14.01M	25.99M	40.08M	81.29M	167.25M	224.67M	47.7M	-35.11M
Operating Margin %	0.16%	0.15%	0.1%	0.13%	0.15%	0.22%	0.25%	0.28%	0.08%	-0.06%
Operating Income Growth %	0.29%	0.16%	-0.12%	0.86%	0.54%	1.03%	1.06%	0.34%	-0.79%	-1.74%
EBITDA+	18.36M	21.31M	24.46M	41.77M	60.95M	108.36M	205.7M	281.68M	133.82M	51.45M
EBITDA Margin %	0.22%	0.2%	0.17%	0.22%	0.23%	0.3%	0.31%	0.35%	0.21%	0.08%
EBITDA Growth %	0.25%	0.16%	0.15%	0.71%	0.46%	0.78%	0.9%	0.37%	-0.52%	-0.62%
D&A (Non-Cash Add-back)	4.59M	5.33M	10.45M	15.78M	20.87M	27.07M	38.45M	57.01M	86.11M	86.56M
EBIT	13.46M	19.22M	13.69M	25.99M	35.44M	71.35M	164.82M	220.3M	59.21M	-6.3M
Net Interest Income+	-32K	-3.77M	-6.44M	-6.71M	-9.29M	-10.39M	-12.54M	4M	-10.03M	-22.57M
Interest Income	0	0	0	0	0	1.74M	176K	6.98M	0	0
Interest Expense	32K	3.77M	6.44M	6.71M	9.29M	12.13M	12.71M	2.98M	10.03M	22.57M
Other Income/Expense	-341K	-4.28M	-6.76M	-4.55M	-13.93M	-22.07M	-13.71M	-5.53M	9M	8.08M
Pretax Income+	13.42M	11.69M	7.25M	21.44M	26.15M	59.22M	153.54M	219.14M	56.71M	-27.04M
Pretax Margin %	0.16%	0.11%	0.05%	0.11%	0.1%	0.16%	0.23%	0.27%	0.09%	-0.04%
Income Tax+	4.08M	11K	-21.11M	4.82M	4.74M	-709K	25.25M	33.18M	21.11M	-1.52M
Effective Tax Rate %	0.7%	1%	3.91%	0.78%	0.82%	1.01%	0.84%	0.85%	0.63%	0.94%
Net Income+	9.35M	11.68M	28.35M	16.62M	21.41M	59.93M	128.29M	185.96M	35.6M	-25.51M
Net Margin %	0.11%	0.11%	0.2%	0.09%	0.08%	0.16%	0.19%	0.23%	0.06%	-0.04%
Net Income Growth %	0.14%	0.25%	1.43%	-0.41%	0.29%	1.8%	1.14%	0.45%	-0.81%	-1.72%
Net Income (Continuing)	9.35M	11.68M	28.35M	16.62M	21.41M	59.93M	128.29M	185.96M	35.6M	-25.51M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.28	0.34	0.72	0.37	0.44	1.11	2.24	3.24	0.63	-0.46
EPS Growth %	0.12%	0.21%	1.12%	-0.49%	0.19%	1.52%	1.02%	0.45%	-0.81%	-1.73%
EPS (Basic)	0.28	0.35	0.74	0.38	0.44	1.14	2.33	3.35	0.64	-0.46
Diluted Shares Outstanding	33.58M	34.1M	39.15M	45.47M	49.21M	53.89M	57.26M	57.45M	56.38M	55.94M
Basic Shares Outstanding	32.88M	33.57M	38.23M	43.77M	48.34M	52.55M	55.02M	55.46M	55.72M	55.94M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	103.25M	184.15M	242.78M	275.74M	641.83M	902.38M	931.68M	998.12M	1.11B	1.07B
Cash & Short-Term Investments	73.41M	141.78M	173.76M	193.82M	528.39M	717.29M	603.81M	623.76M	751.32M	757.36M
Cash Only	73.41M	141.78M	173.76M	193.82M	528.39M	717.29M	603.81M	523.46M	751.32M	757.36M
Short-Term Investments	0	0	0	0	0	0	0	100.3M	0	0
Accounts Receivable	11.45M	16.03M	27.74M	35.75M	43.67M	71.39M	117.42M	116.25M	124.16M	134.12M
Days Sales Outstanding	50.01	55.98	71.68	67.26	58.98	71.14	63.92	52.94	71.67	77.16
Inventory	18M	24.7M	39M	42.26M	54.83M	95.03M	184.49M	238.28M	202.32M	142.96M
Days Inventory Outstanding	186.36	191.31	212.33	179.47	151.6	201.76	241.12	251.49	208.65	145.03
Other Current Assets	917K	662K	1.38M	2.43M	12.13M	14.09M	19.27M	17.41M	19.92M	20.6M
Total Non-Current Assets+	42.98M	104.76M	500.74M	498.88M	758.28M	1B	1.43B	1.53B	1.72B	1.76B
Property, Plant & Equipment	13.8M	14.96M	22.42M	32.18M	74.16M	92.05M	226.52M	315.7M	322.95M	333.12M
Fixed Asset Turnover	6.05x	6.99x	6.30x	6.03x	3.64x	3.98x	2.96x	2.54x	1.96x	1.90x
Goodwill	14.35M	59.55M	327.33M	326.74M	468.41M	618.3M	860.36M	855.51M	987.12M	1.03B
Intangible Assets	12.76M	29.81M	144.75M	135.44M	212.55M	287.1M	337.27M	360.62M	406.96M	397.9M
Long-Term Investments	1.63M	450K	0	0	0	0	0	0	0	0
Other Non-Current Assets	450K	450K	6.23M	174K	238K	573K	615K	815K	1.28M	868K
Total Assets+	146.24M	288.91M	120.41M	139.45M	1.4B	1.9B	2.36B	2.53B	2.83B	2.83B
Asset Turnover	0.57x	0.36x	1.17x	1.39x	0.19x	0.19x	0.28x	0.32x	0.22x	0.22x
Asset Growth %	3.24%	0.98%	-0.58%	0.16%	9.04%	0.36%	0.24%	0.07%	0.12%	-0%
Total Current Liabilities+	18.78M	21.07M	25.21M	129.84M	48.31M	318.96M	375.26M	404.2M	164.94M	126.79M
Accounts Payable	6.72M	5.06M	7.28M	10.49M	11.43M	16.88M	36.2M	27.55M	19.56M	32.13M
Days Payables Outstanding	69.62	39.21	39.64	44.54	31.59	35.84	47.31	29.08	20.18	32.6
Short-Term Debt	0	0	0	103.49M	0	243.74M	255.26M	284.62M	69.45M	0
Deferred Revenue (Current)	258K	408K	960K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	4.68M	5.59M	9.56M	9.95M	19.85M	20.29M	42.15M	47.47M	29.64M	49.29M
Current Ratio	5.50x	8.74x	9.63x	2.12x	13.28x	2.83x	2.48x	2.47x	6.74x	8.41x
Quick Ratio	4.54x	7.57x	8.08x	1.80x	12.15x	2.53x	1.99x	1.88x	5.51x	7.28x
Cash Conversion Cycle	166.74	208.08	244.37	202.18	178.99	237.07	257.72	275.34	260.14	189.59
Total Non-Current Liabilities+	4.71M	99.07M	126.76M	29.21M	292.03M	54.78M	233.03M	216.7M	701.4M	730.16M
Long-Term Debt	0	95.27M	99.25M	0	232.77M	0	0	0	510.14M	525.57M
Capital Lease Obligations	0	0	0	0	27M	26.43M	102.49M	131.39M	126.58M	145.58M
Deferred Tax Liabilities	0	0	25.17M	25.09M	29.94M	27.03M	33.48M	23M	39.32M	22.77M
Other Non-Current Liabilities	4.71M	3.8M	2.34M	4.13M	2.33M	1.32M	97.05M	62.31M	25.35M	36.24M
Total Liabilities	23.49M	120.15M	151.97M	159.05M	340.35M	373.74M	608.29M	620.9M	866.34M	856.95M
Total Debt+	0	95.27M	99.25M	103.49M	263.32M	275.42M	366.05M	422.96M	711.8M	686.25M
Net Debt	-73.41M	-46.51M	-74.51M	-90.33M	-265.07M	-441.88M	-237.76M	-100.5M	-39.52M	-71.11M
Debt / Equity	-	0.56x	0.17x	0.17x	0.25x	0.18x	0.21x	0.22x	0.36x	0.35x
Debt / EBITDA	-	4.47x	4.06x	2.48x	4.32x	2.54x	1.78x	1.50x	5.32x	13.34x
Net Debt / EBITDA	-4.00x	-2.18x	-3.05x	-2.16x	-4.35x	-4.08x	-1.16x	-0.36x	-0.30x	-1.38x
Interest Coverage	430.13x	4.24x	2.17x	3.87x	4.31x	6.70x	13.15x	75.47x	4.76x	-1.56x
Total Equity+	122.75M	168.76M	591.55M	615.57M	1.06B	1.53B	1.75B	1.91B	1.96B	1.97B
Equity Growth %	0.1%	0.37%	2.51%	0.04%	0.72%	0.44%	0.14%	0.09%	0.03%	0%
Book Value per Share	3.66	4.95	15.11	13.54	21.54	28.37	30.56	33.26	34.85	35.27
Total Shareholders' Equity	122.75M	168.76M	591.55M	615.57M	1.06B	1.53B	1.75B	1.91B	1.96B	1.97B
Common Stock	329K	338K	436K	439K	521K	548K	553K	556K	558K	561K
Retained Earnings	-71.54M	-59.86M	-31.51M	-15.57M	5.84M	65.77M	194.06M	397.27M	432.87M	407.35M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-8.57M	-13.75M	-6.36M	-11.89M	-15.03M	2.08M	-16.89M	-34.39M	-37.81M	-52.53M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	15.05M	7.52M	17.45M	32.77M	67.22M	62.63M	119.02M	172.08M	113.92M	175.39M
Operating CF Margin %	0.18%	0.07%	0.12%	0.17%	0.25%	0.17%	0.18%	0.21%	0.18%	0.28%
Operating CF Growth %	-0.18%	-0.5%	1.32%	0.88%	1.05%	-0.07%	0.9%	0.45%	-0.34%	0.54%
Net Income	9.35M	11.68M	28.35M	16.62M	21.41M	59.93M	128.29M	185.96M	41.58M	-25.51M
Depreciation & Amortization	4.59M	5.33M	10.51M	15.78M	20.87M	27.07M	38.45M	57.01M	68.08M	86.56M
Stock-Based Compensation	3.6M	4.59M	6.75M	10.19M	12.85M	17.01M	0	27.32M	25.57M	48.07M
Deferred Taxes	-118K	-4.09M	-24.68M	71K	-624K	-3.99M	6.52M	-1.35M	2.32M	0
Other Non-Cash Items	4.08M	5.51M	4.04M	4.25M	15.33M	11.97M	47.89M	-27.01M	-15M	5.36M
Working Capital Changes	-6.45M	-15.51M	-7.52M	-14.13M	-2.62M	-49.35M	-102.13M	-69.84M	-8.64M	60.92M
Change in Receivables	-3.73M	-3.22M	-6.89M	-6.1M	-5.68M	-20.89M	-46.52M	-3.6M	-3.31M	-14.03M
Change in Inventory	-6.15M	-6.16M	605K	-4.04M	-10.8M	-29.99M	-89.78M	-57.2M	40.97M	56.9M
Change in Payables	3.02M	-1.8M	807K	2.27M	662K	2.46M	19.52M	-8.2M	-9.8M	12.9M
Cash from Investing+	4.79M	-49.19M	-98.25M	-14.04M	-205.31M	-201.38M	-221.17M	-233.24M	-123.28M	-86.38M
Capital Expenditures	-2.63M	-4.33M	-5.45M	-14.04M	-18.5M	-22.45M	-71.28M	-84.83M	-36.22M	-25.68M
CapEx % of Revenue	0.03%	0.04%	0.04%	0.07%	0.07%	0.06%	0.11%	0.11%	0.06%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	27.59M	45K	450K	-3.4M	-4.65M	-3.89M	0	-48.4M	-2.73M	-5.94M
Cash from Financing+	767K	112.11M	129.94M	3.41M	484.87M	305.92M	961K	-13.34M	248.96M	-82.9M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	767K	1.04M	636K	3.42M	677K	8.14M	-2.9M	-13.34M	-26.75M	-17.26M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	12.43M	3.2M	12M	18.73M	44.06M	36.28M	47.74M	38.74M	74.93M	142.49M
FCF Margin %	0.15%	0.03%	0.08%	0.1%	0.16%	0.1%	0.07%	0.05%	0.12%	0.22%
FCF Growth %	-0.03%	-0.74%	2.75%	0.56%	1.35%	-0.18%	0.32%	-0.19%	0.93%	0.9%
FCF per Share	0.37	0.09	0.31	0.41	0.90	0.67	0.83	0.67	1.33	2.55
FCF Conversion (FCF/Net Income)	1.61x	0.64x	0.62x	1.97x	3.14x	1.05x	0.93x	0.93x	3.20x	-6.87x
Interest Paid	0	1.22M	2.44M	2.44M	1.48M	1.07M	0	1.03M	988K	6.07M
Taxes Paid	4.95M	3.99M	4.02M	4.05M	6.5M	10.28M	0	34.37M	26.96M	19.3M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	7.97%	8.01%	7.46%	2.75%	2.56%	4.63%	7.82%	10.16%	1.84%	-1.3%
Return on Invested Capital (ROIC)	20.84%	13.96%	3.29%	3.74%	4.56%	6.48%	9.65%	10.14%	1.92%	-1.38%
Gross Margin	57.8%	54.93%	52.53%	55.7%	51.15%	53.06%	58.35%	56.85%	44.03%	43.29%
Net Margin	11.19%	11.17%	20.07%	8.56%	7.92%	16.36%	19.13%	23.2%	5.63%	-4.02%
Debt / Equity	-	0.56x	0.17x	0.17x	0.25x	0.18x	0.21x	0.22x	0.36x	0.35x
Interest Coverage	430.13x	4.24x	2.17x	3.87x	4.31x	6.70x	13.15x	75.47x	4.76x	-1.56x
FCF Conversion	1.61x	0.64x	0.62x	1.97x	3.14x	1.05x	0.93x	0.93x	3.20x	-6.87x
Revenue Growth	31.45%	25.14%	35.1%	37.38%	39.28%	35.53%	83.08%	19.54%	-21.11%	0.33%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	270.1M	366.14M	670.32M	801.18M	638.38M	634.18M
Product Growth	-	-	-	-	35.56%	83.08%	19.52%	-20.32%	-0.66%
Filtration Products	19.77M	49.05M	90.59M	119.53M	174.9M	403.5M	495.93M	347.78M	372.96M
Filtration Products Growth	-	148.05%	84.68%	31.96%	46.31%	130.71%	22.91%	-29.87%	7.24%
Chromatography Products	29.52M	36.31M	45.33M	64.64M	73.55M	91.04M	131.68M	126.63M	122.81M
Chromatography Products Growth	-	23.00%	24.83%	42.60%	13.79%	23.77%	44.64%	-3.84%	-3.02%
Proteins Products	-	-	-	65.12M	80.73M	123.71M	114.32M	103.46M	74.42M
Proteins Products Growth	-	-	-	-	23.97%	53.23%	-7.59%	-9.50%	-28.07%
Process Analytics Products	-	-	-	16.41M	33.35M	48.02M	53.51M	56.82M	59.3M
Process Analytics Products Growth	-	-	-	-	103.27%	44.00%	11.44%	6.18%	4.37%
Other products	431K	1.76M	3.6M	4.4M	3.61M	4.05M	5.74M	3.69M	4.68M
Other products Growth	-	308.58%	104.66%	22.06%	-17.91%	12.18%	41.72%	-35.76%	26.87%
Protein Products	54.72M	53.97M	54.38M	-	-	-	-	-	-
Protein Products Growth	-	-1.37%	0.75%	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Repligen Corporation (RGEN) reported $707.9M in revenue for fiscal year 2024. This represents a 2494% increase from $27.3M in 2011.

Repligen Corporation (RGEN) grew revenue by 0.3% over the past year. Growth has been modest.

Yes, Repligen Corporation (RGEN) is profitable, generating $1.7M in net income for fiscal year 2024 (-4.0% net margin).

Dividend & Returns

Repligen Corporation (RGEN) has a return on equity (ROE) of -1.3%. Negative ROE indicates the company is unprofitable.

Repligen Corporation (RGEN) generated $106.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.